Vanda settles its squabble with Novartis and pockets $25M for its trouble

Vanda Pharmaceuticals ($VNDA) has come out at the other end of its dispute with former partner Novartis ($NVS), getting back the rights to its schizophrenia drug and banking an equity investment from the Swiss drugmaker.

In 2009, Novartis bought the U.S. and Canadian rights to Vanda's Fanapt in a deal worth up to $465 million, working to crack the market with what many perceived as a me-too drug. Fanapt never lived up to the partners' hopes, however, and the deal bubbled over into a dispute this May, with Vanda demanding $539 million and Novartis responding with a counter claim.

Now, under the pair's final agreement, Vanda regains the full rights to Fanapt, and Novartis has agreed to make a $25 million investment in the company. Vanda also gets a worldwide exclusive license to Novartis' AQW051, a Phase II treatment for schizophrenia.

The deal "has the potential to be transformational for our company," CEO Mihael Polymeropoulos said in a statement, and the news sent Vanda's shares soaring more than 20% on Tuesday morning.

Beyond Fanapt, Vanda's portfolio includes Hetlioz, approved early this year to treat a sleep disorder called non-24, and VLY-686, an anti-itching drug.

- read the statement

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.